UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 ______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-389 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O R 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-3898435 (State or other jurisdictio ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. CORPORATE PRESENTATION September 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in t ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 2Q22 CORPORATE PRESENTATION AUGUST 3, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 1Q22 Corporate Presentation May 9, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Katherine Bock - VP, IR & Corporate Strategy Terry Rosen - Co-Founder, Chairman & CEO Robert Goeltz - Principal Financial & Accounting Officer & CFO Jennifer Jarrett - COO & Director Juan Jaen - Co-Founder, President & Director Kartik Krishnan - SVP, Clinical Development Conference Call Participants Alethia Young - Cantor Fitzgerald & Co. Peter Lawson - Barclays Bank Geoffrey Porges - SVB Leer ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | OUR VISION: COMBINING TO CURE | | | | | | | | | | | | | | WITH BEST-IN-CLASS CANCER THERAPIES | | | | | | | | | | | | | | CORPORATE OVERVIEW | | | | | | | APRIL 2021 | | | | | | | NYSE: RCUS | | | | | | Forward-looking Statements/Safe Harbor This presentation contains forward-loo ...

OUR VISION: COMBINING TO CURE WITH BEST-IN-CLASS CANCER THERAPIES COWEN HEALTHCARE CONFERENCE MARCH 2, 2021 NYSE: RCUS Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding future events or results contained in this presentation are forward-looking statements, including statements ab ...